PanaceAR_NecroSense-Burns-Chronic-Skin-Wounds_vignetage

COMPLETE DEBRIDEMENT FOR BURNS & DIABETIC ULCERS

A next generation Biomarker for treating Life-Threatening Diseases

PanaceAR_diagnosis_Cancer

TARGETING DIAGNOSIS & THERAPY IN CANCER

A next generation Biomarker for treating Life-Threatening Diseases

PanaceAR_Improving-Patients-Lives

SPEEDING UP CARE & PROVING THERAPY

A next generation Biomarker for treating Life-Threatening Diseases

We bring innovation
to multiple indications

We have a robust pipeline of future products
with a current focus on burns, diabetic foot ulcers and breast cancer applications.

Revolutionizing diagnosTICS &
therapeuticS INTO A THERANOSTIC PLATFORM

We have developed and patented a revolutionary Biomarker which targets necrotic tissue i.e dead cells. Necrosis only occurs in pathological conditions including burns, skin wounds, cardiovascular diseases and is prevalent in the core of about 80% of all solid tumours.

Imaging and quantifying the amount of necrotic tissue in cancer provides us with a new diagnostic platform, as the amount of necrosis indicates the location and aggressiveness of a tumour. 

Our biomarker will also deliver therapies precisely at the core of tumours and the percentage increase in necrotic volume this causes, indicates the efficacy of those therapies. 

 The combination of necrosis based diagnostics and targeted therapy forms the basis of our new theranostic platform

MECHANISM OF ACTION
at the cellular level

Our Biomarker is a very bright near Infrared Fluorescent
compound that specifically binds to dead cells.

LIVE CELL

A live and healthy cell contains proteins, DNA and is impermeable to our Biomarker.

Necrotic Dead Cell

But when the cell dies and becomes necrotic, the cell membrane will rupture, enabling our biomarker to bind to intracellular denatured proteins that become available.

Burn wound is visualized by NecroSense (in green) in an ex vivo human skin sample (autofluorescence of healthy skin in red)

NecroSense

Biomarker imaging burns & chronic skin wounds

DIAGNOSIS

Surgeons can distinguish between healthy and necrotic tissue

SURGERY

Enables real time visualization of dead tissue during debridement surgery

HEALING

Accurate debridement will give better attachment of the skin graft and prevents rejection due to necrosis-induced inflammation

PATIENT EXPERIENCE

Shortens operations with less morbidity and annuls re-operations due to necrosis-induced rejection

NecroSense Application

NecroPET

Radioactive biomarker for diagnosis & treatment of solid tumours

Screening

Indicates the presence of a serious disease

Diagnosis

Determines the aggressiveness of the tumor

Therapy efficacy

Validates the efficacy of anticancer therapy

SURGERY

Real time visualization of tumor tissue ensuring complete resection

Treatment

Delivers therapeutics accurately

NecroPet ApplicationS

Rapid Screening & Diagnosis

Rapid monitoring Therapy Efficacy

Image Guided Surgery

Accurate & Complete

Therapy

Targeted & Precise

Our team

Experienced. Committed.

ROBERT BRETON

Co-Founder & CEO

20 years Executive Experience
Lean Startups
Investor relations
Board Mandates

HERB HEYNEKER

Co-Founder & Member of Advisory Board

Board of Directors of US and Dutch companies
Advisor to various biotech startups
+ 50 peer-reviewed papers
+ 30 US patents

PROF. Dr. CLEMENS LOWIK

Scientific Advisor

Prof Optical Molecular Imaging
Co-founder of several Startups
7 Patents
Founder & President of ESMI

GERARD KRIELEN

Member of Advisory Board

Study Chartered Accountant completed in 1993
25 years of CFO experience
Financing and M&A transactions
Private Investor in Medical Startups

DR. MIRRE DE NOO

Medical Advisor


Managing director Reggeborgh Medical
Surgeon at Equipe healthcare companies
Member of the Supervisory Board of the Population Screening North

LOEKI SCHAEFFERS

Strategy & Sustainability Advisor

Expert on Market Transformation, Circular Economy, Sustainability Transitions and Programme Management. 
Founder of InterconnACT 

JULIETTE BORDET

Business Development & Marketing Manager

PharmD.
Specialised Master in Biopharmaceutical
Management at ESCP Europe
Experiences in Startup and Medical Devices Industries

Latest

Do you have any questions?

Please contact us with the form below